drugset / Trial / NCT00750841
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.
Timeline
- Start
- 2008-09-09
- Primary completion
- 2009-07-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | 45 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | — |